Sonic Healthcare delivered a strong FY2026, with underlying net profit up 17% to A$621 million and dividends rising to A$1.08 per share. The next test is whether US efficiencies, LADR synergies and organic growth can offset Swiss fee cuts, a delayed UK contract ramp-up and heavier investment demands.
- Underlying net profit rose 17% to A$621 million
- Revenue increased 13% to A$10.9 billion, including 5% organic growth
- LADR contributed A$59.1 million of net profit after tax
- US operating initiatives are expected to add A$25-A$30 million to FY2027 earnings
- Three-year executive LTI awards recorded zero vesting
Strong earnings, but the easy comparison is over
Sonic Healthcare Limited (ASX:SHL) finished FY2026 with the kind of headline numbers that make a diagnostics business look reassuringly predictable: revenue rose 13% to A$10.9 billion, underlying EBITDA increased 11% to A$1.93 billion and underlying net profit climbed 17% to A$621 million. Organic revenue growth was 5%, operating cash flow reached A$1.41 billion and total dividends increased to A$1.08 per share.
The statutory figures were lower after non-recurring items. Net profit attributable to Sonic shareholders was A$608.3 million, compared with underlying net profit of A$621.0 million, while statutory EBITDA was A$1.882 billion. The adjustments included a A$106.7 million gain from the Brisbane laboratory sale and leaseback, a A$82.8 million software impairment, a A$33.0 million US debtors adjustment, Australian wage remediation and restructuring costs.
LADR becomes Germany’s main growth engine
The year’s most significant acquisition, Germany’s Laboratory Group Dr. Kramer & Colleagues, or LADR, contributed A$707.3 million of revenue and A$59.1 million of net profit after tax after being acquired on 1 July 2025. Sonic said the return on the acquisition was already above its cost of capital, with further synergies expected from procurement, shared services, specialist testing, logistics and national laboratory infrastructure.
Germany is now Sonic’s largest market by revenue, accounting for 25% of the group total. Statutory German revenue grew 43%, although that figure includes LADR; organic growth was 5%. At the beginning of FY2027, Sonic reorganised its German operations from 11 federation members into three divisions, a move management says is designed to accelerate consolidation and efficiency gains.
The acquisition also brought Poland into Sonic’s geographic footprint and helped lift European laboratory revenue. It came alongside the US acquisition of Cairo Diagnostics, whose advanced diagnostics platform supported 16% organic growth in Sonic’s newly formed US Advanced Diagnostics division.
United States restructuring offers a measurable FY2027 lever
The United States remains less tidy. Underlying organic revenue growth was 2% after adjusting for the loss of a major Alabama payer contract and the rationalisation of part of the anatomical pathology operations. Sonic has rationalised nine anatomical pathology practices, reduced central corporate headcount and pursued procurement, reference-testing and support-function efficiencies.
Management expects cost initiatives locked in to date to add A$25 million to A$30 million to FY2027 earnings. That is an expectation rather than a guarantee, and the report also records an A$33 million EBITDA hit from a US debtors adjustment related to revenue recognised in FY2024 and FY2025. More than 70% of US dermatopathology volume is now processed through Sonic’s PathologyWatch digital platform, adding a technology angle to the restructuring story.
Swiss fee cuts and UK delays temper the outlook
Sonic’s main disclosed offsets sit outside the US. Regulatory changes in Switzerland from 1 July 2026 are expected to reduce FY2027 revenue by about CHF20 million through fee reductions affecting 10 high-volume tests. In the UK, the Hertfordshire and West Essex NHS contract delivered strong revenue growth, but testing-volume transfers into the new Watford hub have progressed more slowly than anticipated because of operational issues within the NHS. Planned contract margins are now expected in the second half of FY2028.
The balance sheet leaves room to keep investing. Net interest-bearing debt, excluding lease liabilities, rose 9% to A$3.07 billion, while debt cover was 2.2 times and available liquidity was approximately A$1.6 billion. Sonic completed the Brisbane sale and leaseback for A$445 million and is evaluating further property transactions, but net interest expense also increased 19% as acquisition-related borrowings flowed through.
New leadership inherits a tougher scorecard
Dr Jim Newcombe completed his first ten months as chief executive and managing director after Dr Colin Goldschmidt’s retirement following 32 years in the role. The transition appears operationally steady, but the remuneration report contains a less flattering long-term signal: no options or performance rights from the three-year period to 30 June 2026 vested. Relative TSR ranked at the 15th percentile, aggregate constant-currency EPS was 316.7 cents against a minimum hurdle of 457 cents, and average ROIC reached 77.1% of target.
That result sits alongside a strong one-year earnings performance and exposes the difference between recovering annual profit and creating sustained shareholder returns. Sonic plans to invest about A$30 million a year for three years in back-office digital systems, while its new Melbourne Docklands hub is due to open in mid-2027. The next phase therefore asks management to convert acquisition scale and technology spending into better returns, not simply larger revenue.
Climate reporting starts with a reset
Sonic’s first mandatory AASB S2 climate disclosures reported 35,058 tonnes of Scope 1 emissions, 82,029 tonnes of Scope 2 location-based emissions and 59,983 tonnes on a market-based basis. PwC provided limited assurance over specified governance, strategy and Scope 1 and 2 disclosures. However, Sonic reset its emissions base year from FY2021 to FY2026 and had no active climate targets in place at the reporting date while it re-establishes them.
The company said it expects to reinstate its previous net-zero-by-2050 commitment and interim targets in its November 2026 Sustainability Impact Report. That report, the FY2027 earnings contribution from US restructuring, the progress of the Watford contract and the impact of Swiss fee reductions will provide a more demanding test of whether FY2026’s strong result marks durable operating improvement or simply a favourable year in the acquisition cycle.
Bottom Line?
Sonic enters FY2027 with solid cash generation and acquisition momentum, but the crucial evidence will be whether restructuring and synergies lift returns while the UK, Swiss and digital investment programs absorb capital.
Questions in the middle?
- Will the promised A$25 million to A$30 million US earnings benefit arrive without further revenue or debtor adjustments?
- How quickly can the Watford NHS contract reach its planned margins after the integration delay?
- Can Sonic’s reset climate targets remain ambitious while the group expands through acquisitions and digital infrastructure spending?